Furberg, Full Drug Safety Committee To Be Present At COX-2 Meeting
Wake Forest University epidemiologist Curt Furberg will participate with FDA's full Drug Safety & Risk Management Advisory Committee in the upcoming review of the COX-2 inhibitor therapeutic class
You may also be interested in...
Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review
Covance will develop and operate a single, enhanced risk management program for all four isotretinoin products
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011